Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease

Pampín-Sánchez, Rubén; Martínez-Mugica-Barbosa, Cristina; Fonseca-Aizpuru, Eva María; Barbazán-Vázquez, Francisco Javier; Fernández-González, Beatriz; Buznego-Súárez, Loreto.
Med. clín (Ed. impr.) ; 160(3): 113-117, febrero 2023. tab, ilus
Artículo en Inglés | IBECS (España) | ID: ibc-215519

Documentos relacionados

  1. Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease.
  2. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study.
  3. Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT.
  4. Orbital Radiation for Thyroid Eye Disease: A Report by the American Academy of Ophthalmology.
  5. Disease Modulation Versus Modification: A Call for Revised Outcome Metrics in the Treatment of Thyroid Eye Disease.
  6. Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values.
  7. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
  8. [Research status of potential therapeutic targets for thyroid-associated ophthalmopathy].
  9. The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials.
  10. Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease.